Thu. Feb 6th, 2025

Merck & Exelixis Test Zanzalintinib With Keytruda In Head/Neck Cancer, Welireg In Renal Cancer

ByLisa Luckas

10/14/2024
After 63 years of service, the early hours of March 28 saw the last night flights for transporting letter mail between northern and southern Germany.After 63 years of service, the early hours of March 28 saw the last night flights for transporting letter mail between northern and southern Germany.After 63 years of service, the early hours of March 28 saw the last night flights for transporting letter mail between northern and southern Germany.
  • Merck & Exelixis collaborate to evaluate Zanzalintinib with KEYTRUDA in head and neck cancer and with WELIREG in renal cell carcinoma.

Mon Oct 14 13:01:46 -0000 2024 UTC– Merck & Co., Inc. announced a collaboration with Exelixis to study Zanzalintinib with KEYTRUDA in head and neck cancer and with WELIREG in renal cell carcinoma. For more details, visit the company’s website.

Recently, Merck in New Jersey announced FDA approval for KEYTRUDA plus chemotherapy for mesothelioma treatment.

In the U.S., KEYTRUDA, in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or GEJ adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test.

 

Nobot.News is not a bot, but powered by generative AI. Here’s the full disclosure:

About Lisa

Subscribe to Lisa’s Newsletter today!

Keep Up: Nobot.News Launches Breaking Newsletter

Read more Business News as it happens!

Business

Stop smoking to avert cancer.
News from ESMO.

ByLisa Luckas

Lisa Luckas is a Sr. Business News Editor at Nobot.News.

Leave a Reply

Your email address will not be published. Required fields are marked *